Curebase, Inc.
13 articles about Curebase, Inc.
-
Curebase Launches All-in-One Software and Trial Execution Package to Help Digital Therapeutics Companies Accelerate Clinical Trials
1/24/2023
Curebase, a company committed to democratizing access to clinical trials, announced the release of its integrated software and services package for digital therapeutics trials that accelerates enrollment and allows sponsors to launch their studies faster.
-
Curebase Partners with Redenlab to Expand Data Capture Capabilities in Pharma Trials
12/1/2022
Curebase, a company dedicated to democratizing clinical trials through a decentralized model is announcing its partnership with Redenlab, a global leader for speech testing in industry-run clinical trials.
-
Curebase and BEKHealth Join Forces to Expand Access to Decentralized Clinical Trials
11/15/2022
Curebase to Leverage BEKHealth's Integrated Clinical Research Platform to More Easily Find and recruit Decentralized Trial Participants, Expand into Oncology and New Therapeutic Areas.
-
Curebase Names Medical Research Veteran Sean Lynch as VP of Clinical Operations
8/23/2022
Curebase, a company committed to democratizing access to clinical studies, has named veteran clinical research executive Sean Lynch as vice president of clinical operations.
-
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
-
Curebase, Flow Neuroscience Announce Joint Clinical Trial for the use of an at-home tDCS device for treating depression
5/17/2022
Curebase, a company committed to democratizing access to clinical studies, and Flow Neuroscience, creator of Europe's only medically approved transcranial direct current stimulation (tDCS) device and behavioral therapy app for depression, are launching a clinical trial in which participants will test the effectiveness of Flow's at-home headset in reducing depressive symptoms.
-
Curebase Secures $40 Million in Series B Funding
5/5/2022
Curebase has raised $40 million in Series B funding to continue development of its end-to-end clinical trial execution model, virtual and hybrid site capabilities, and full eClinical software platform to run modern, patient-centric clinical trials.
-
Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage their Health
3/7/2022
Curebase, a company committed to democratizing access to clinical studies, and Blue Note Therapeutics, a prescription digital therapeutics (PDT) company dedicated to easing the burden of cancer and improving outcomes, have announced a collaboration on a virtual clinical trial that will study the effectiveness of two digital therapeutics.
-
Curebase Adds Two Clinical Trial Veterans to Kick-off New Advisory Board
2/14/2022
Curebase, a company committed to democratizing access to clinical studies, has named Dr. Aaron Kamauu and Dr. Amir Lahav to the Curebase Advisory Board.
-
Curebase and Persephone Biosciences Partner in Clinical Trial of Colorectal Cancer Among Diverse Populations
1/11/2022
Curebase and Persephone Biosciences today announced a collaboration for the long-term clinical study of patients with colorectal cancer (CRC).
-
Curebase Technology Key to metaMe Health's FDA Clearance of Regulora
12/16/2021
Curebase, a company committed to democratizing access to clinical studies, is pleased to have served as the technology partner for metaMe Health's Regulora®, the first FDA-authorized treatment of any kind specifically for abdominal pain associated with irritable bowel syndrome (IBS) in adults.
-
Curebase, InBios Announce Results of Virtual Clinical Trial of InBios COVID-19 Rapid Detection Test Using Curebase Platform
7/14/2021
Curebase today announced that InBios successfully utilized Curebase's virtual site solution to power clinical studies for its SCoV-2 Ag Detect™ Rapid Test, which was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on May 6, 2021.
-
Curebase Unlocks Drug Development With Remote Clinical Trials; Raises $15M Led By GGV Capital
5/25/2021
Curebase announced $15M in Series A funding to continue developing its decentralized clinical trial software platform and virtual research site capabilities, powering research where any patient, anywhere, can be part of clinical trials at home and with their own doctor.